Insmed

INSM

Market cap $34.8B

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Will Lewis, Insmed CEO, joins 'Fast Money' to talk the rare disease pipeline, acquisitions in the pharma space, and more.

Shares of Insmed rise after it tops FY25 sales forecasts, led by strong Brinsupri uptake, and outlines 2026 guidance and pipeline milestones.

Insmed Inc (NASDAQ: INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launches that could shape the company's growth over the next 18 months.

— BRINSUPRI®  (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025— —ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2025 with Unaudited Global Revenues of Approximately $433.8 Million— —Full-Year 2026 Global ARIKAYCE Revenues Expected to be Between $450 Million and $470 Million— —Topline Data from Phase 3 ENCORE Study of ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Disease Now Anticipated in March or April of 2026— — Topline Data from Phase 2b CEDAR Study of Brensocatib in Patients with HS Now Anticipated in the Second Quarter of 2026— — Phase 3 PALM-ILD Study of TPIP in PH-ILD Initiated in the Fourth Quarter of 2025; Additional Phase 3 Studies Planned for PAH, PPF, and IPF in 2026— BRIDGEWATER, N.J., Jan. 9, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today provided an update on the Company's commercial and clinical programs and its outlook for 2026.

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Insmed shares surged on FDA and EU approvals of Brinsupri, strong uptake, and a growing pipeline which fueled optimism around its revenue outlook.

BRIDGEWATER, N.J., Jan. 2, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the J.P.